When a T cell recognizes an antigen, the TCR complex triggers a cascade of phosphorylation events. HPK1 is recruited to the signalosome and phosphorylates SLP-76 (at Serine 376). This phosphorylation event creates a docking site for the E3 ubiquitin ligase Itch, leading to the degradation of SLP-76 and ultimately dampening the activation of MAP kinases (ERK, JNK) and NF-κB. In simple terms: HPK1 puts a brake on T cell activation.
The versatility of KBI-092 lies in its potential to treat a range of conditions. Preliminary research and preclinical studies suggest that KBI-092 may be effective in: KBI-092
The mechanism of action of KBI-092 involves the selective inhibition of a particular target, which could be an enzyme, receptor, or protein critical in the disease process. By modulating this target, KBI-092 aims to restore normal physiological functions or mitigate the pathological processes leading to disease progression. The specificity of KBI-092 towards its target is believed to confer a favorable safety profile while maximizing therapeutic efficacy. When a T cell recognizes an antigen, the
KBI-092 is a small molecule inhibitor designed to target specific biological pathways implicated in various diseases. While the exact details of its chemical structure and formulation might not be publicly disclosed due to ongoing research and patent protections, its development signifies a breakthrough in the quest for more effective and safer therapeutic options. In simple terms: HPK1 puts a brake on T cell activation
Unlike large-molecule biologics (antibodies), KBI-092 is a small molecule. In preclinical models, it demonstrated excellent oral bioavailability (often >50% in rodent models), allowing for chronic dosing. This oral route offers a significant patient convenience advantage over intravenous checkpoint inhibitors.